Evaluation of Votrient in Angiosarcoma (EVA)
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
Sponsor: Hannover Medical School
Terminated
Due to interim analysis' results and definitions fixed in protocol
Other terminated trials from Hannover Medical School
A PHASE2 clinical study on Angiosarcoma, this trial is terminated or withdrawn. The trial is conducted by Hannover Medical School and has accumulated 10 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Feb 2021 — Apr 2022 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Unknown Status PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Nov 2018 — Apr 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hannover Medical School
- Heidelberg University
- Helios Klinikum Berlin-Buch
- Klinikum der Universitaet Muenchen, Grosshadern
- Medical University Innsbruck
- Medical University of Graz
- Medical University of Vienna
- Novartis Pharmaceuticals
- University Hospital Dresden
- University Hospital, Essen
- Universitätsklinikum Hamburg-Eppendorf
- Universitätsmedizin Mannheim
For direct contact, visit the study record on ClinicalTrials.gov .